Search Results

You are looking at 71 - 80 of 198 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Radhika Gangaraju, Soo J. Kim, Jing-Fei Dong, Sabina Swierczek, and Josef T. Prchal

, renal dysfunction, and fever. 1 Only a minority of patients present with all of these symptoms, which overlap with other clinical conditions, posing a diagnostic challenge. 2 Acquired TTP occurs due to development of inhibitory antibodies against von

Full access

Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul, and Daniel Becker

-related autoimmune retinopathy and was referred to an oncologist for further evaluation. She had no detectable antiretinal antibodies. She was a nonsmoker with no significant past medical history. She denied weight loss, fever, abdominal pain, dysuria, vaginal

Full access

were in distress because they were not prepared to witness the patient’s experience, especially with CRS, with 105° fevers, and patients wrapped in ice and bear huggers, not to mention the neurotoxicity,” she said. Patients and caregivers also seemed

Full access

Presenter: Aaron T. Gerds

70% of patients have symptoms driven primarily by cytokines, such as fevers and night sweats. Many patients also experience cytopenias, particularly anemia and thrombocytopenia. 2 , 3 “And, of course, it is a disease that carries a shortened life

Full access

Presenter: Natalie S. Callander

(84%), its severity was limited in most participants. “Patients typically develop a fever, chills, or changes in blood pressure within 24 hours of receiving idecabtagene vicleucel, but most are responsive to tocilizumab or steroids,” said Dr. Callander

Full access

Presenter: Maria Alma Rodriguez

, and rubella (MMR), oral typhoid, yellow fever, rotavirus, nasal influenza, and varicella—are contraindicated or should be used with caution in actively immunocompromised cancer survivors and their close contacts. Per the NCCN Guidelines, live

Full access

Atish D. Choudhury and Philip W. Kantoff

was accompanied by increased toxicity compared with mitoxantrone, with higher rates of grade 3 or greater neutropenia (82% vs. 58%), neutropenic fever (8% vs. 1%), and diarrhea (6% vs. <1%), along with greater requirements for dose reductions (12% vs

Full access

Gary H. Lyman and Marek S. Poniewierski

) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients . Support Care Cancer 2013 ; 21 : 1487 – 1495 . 43. Talcott JA Siegel RD Finberg R . Risk assessment in cancer patients with fever and

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

defined using one of the following methods: (1) neutropenia (ICD-9 code 288.0) and fever (ICD-9 code 780.6) within 7 days of hospitalization; (2) absolute neutrophil count (ANC) <1,000/mcL and fever (ICD-9 code 780.6) within 7 days of hospitalization; (3

Full access

Maxim Norkin and John R. Wingard

disseminated infection less commonly seen. Candida infections of the mucosa occur early and throughout the course of neutropenia and/or immunosuppressive therapy. Candida fungemia is rarely the cause of first neutropenic fever, but may be a cause of